Congress moves to strip PBMs of hidden rebate profits, force drug-cost transparency

What it does

This bill prohibits pharmacy benefit managers (PBMs)—the middlemen who manage prescription drug benefits for health plans—from earning money based on drug prices, rebates, or discounts starting January 1, 2027. PBMs can only charge flat-fee service charges for actual work performed, and all rebates and discounts must flow directly to health plans and patients. Violators face $10,000-per-day civil penalties and must return illegally obtained payments.

Why we flagged it

The bill's core mechanism is a direct prohibition on PBM revenue streams tied to drug prices and rebates, coupled with a mandate for transparent flat-fee pricing. This is structural reform of the PBM business model, not a subsidy, carve-out, or commemorative measure.

What the text implies

• PBMs may respond by raising flat-fee charges to compensate for lost rebate revenue, potentially shifting costs from drug-price opacity to explicit service fees—the net effect on patient out-of-pocket costs depends on enforcement and plan design.
• The bill applies only to group health plans and individual coverage under the Public Health Service Act, ERISA, and IRC § 9826; Medicare Part D and Medicaid PBM arrangements are not explicitly addressed, creating a potential regulatory gap.
• Defining 'bona fide service fee' as 'fair market value' of services the entity would otherwise perform requires subjective valuation and may invite litigation over what constitutes a legitimate flat fee versus a disguised rebate.
• Interim final regulations (not notice-and-comment) compress the rulemaking timeline and may result in incomplete guidance on compliance, particularly for complex PBM operations involving mail-order pharmacies, specialty drugs, and network contracting.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Ordinary people and employers benefit by eliminating PBM financial incentives to inflate drug prices and hide rebates. Forcing transparent, flat-fee pricing and requiring rebates to flow through to plans and patients directly lowers net drug costs and increases price transparency. The restriction on PBM revenue is a restraint on a private intermediary's ability to extract value, not a restraint on citizens' rights or remedies.

Who stands to gain

• group health plans (employers and unions)
• individual health insurance enrollees
• patients (via lower net drug costs and rebate pass-through)

Named in the bill

pharmacy benefit managers (PBMs), group health plans, health insurance issuers, Secretary of Health and Human Services, Secretary of Labor, Secretary of the Treasury, Public Health Service Act (Part D, Title XXVII), Employee Retirement Income Security Act (ERISA), Internal Revenue Code (IRC § 9826)

Where it stands

6 cosponsors: 4 Democrats, 2 Republicans.

• Mar 18, 2025 — Introduced · Congress.gov: “Introduced in House”
• Mar 18, 2025 — Referred to House Committee on Education and Workforce and House Committee on Ways and Means · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

19 lobbying clients named this bill on 23 disclosure filings across 3 quarters, Dec 2025 to Jun 2026. Those filings disclosed $38,552,656 in lobbying spend. A filing names 15 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 96% of bills with at least one filing.

Mariannette Miller-Meeks, the sponsor, reported $2,407,952 in PAC receipts in the 2026 cycle. $13,500 of that came from 4 PACs tied to these lobbying clients.

• Pharmaceutical Research and Manufacturers of America — $15,770,000 on 2 filings
• Pharmaceutical Care Management Association — $6,472,656 on 2 filings
• Elevance Health, Inc. — $4,010,000 on 2 filings
• CVS Health (and Subsidiaries) — $3,570,000 on 1 filing
• America's Health Insurance Plans Inc (ahip) — $3,010,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.